Literature DB >> 19086878

Treatment of status epilepticus.

Laura C Miller1, Frank W Drislane.   

Abstract

Generalized convulsive status epilepticus is a neurologic and medical emergency, with significant morbidity and mortality. First-line treatment includes administration of intravenous benzodiazepines. Second-line agents include intravenous phenytoin, phenobarbital, valproate and levetiracetam. Refractory status epilepticus necessitates the use of anesthetic agents such as pentobarbital, midazolam or propofol, with monitoring of treatment effect by continuous EEG. Nonconvulsive status epilepticus should be treated expeditiously but is not as threatening to health as convulsive status epilepticus.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19086878     DOI: 10.1586/14737175.8.12.1817

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  4 in total

1.  Dynamic loss of surface-expressed AMPA receptors in mouse cortical and striatal neurons during anesthesia.

Authors:  Charlene Carino; Eugene E Fibuch; Li-Min Mao; John Q Wang
Journal:  J Neurosci Res       Date:  2011-09-19       Impact factor: 4.164

Review 2.  Management of refractory status epilepticus in adults: still more questions than answers.

Authors:  Andrea O Rossetti; Daniel H Lowenstein
Journal:  Lancet Neurol       Date:  2011-10       Impact factor: 44.182

3.  Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats.

Authors:  Pramod K Dash; Sara A Orsi; Min Zhang; Raymond J Grill; Shibani Pati; Jing Zhao; Anthony N Moore
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

4.  Low dose of valproate improves motor function after traumatic brain injury.

Authors:  Yu-Ting Tai; Wen-Yuan Lee; Fei-Peng Lee; Tien-Jen Lin; Chia-Lin Shih; Jia-Yi Wang; Wen-Ta Chiu; Kuo-Sheng Hung
Journal:  Biomed Res Int       Date:  2014-02-06       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.